QuidelOrtho Reports Third Quarter 2026 Financial Results

QuidelOrtho’s Q3 2026 revenue fell 12% year over year to $619 million, while adjusted EBITDA declined to $148 million from $177 million; GAAP net loss was $54 million and adjusted diluted EPS was $0.31. Revenue grew 2% reported, or 3% in constant currency, excluding respiratory, China, and U.S. Donor Screening, but Point of Care revenue fell 27% amid a softer respiratory season and China pricing pressure. The company narrowed its 2026 guidance ranges and launched a restructuring program targeting over $80 million in annual savings in 2027, with $30–$35 million of expected Q4 2026 charges.

Analysis

QDEL | Cash conversion is the key risk, not the adjusted-savings headline. The $80m 2027 target is material relative to the current EBITDA base, but investors should discount it until delivery is visible: restructuring charges begin in Q4, while execution can disrupt service, product investment, and customer retention in an installed-base business. The quarter’s near-zero free cash flow and negative year-to-date operating cash flow make the savings claim a balance-sheet issue as much as a margin opportunity. Inventory has also risen since year-end. With $166m cash against $424m current borrowings and $2.5bn long-term borrowings, verify the maturity schedule, available liquidity, and covenant headroom; the supplied figures alone do not establish refinancing stress.

Near term (days): narrowed guidance cuts the upside ceiling for EBITDA and EPS while leaving floors unchanged. That reduces the near-term earnings-revision catalyst, though the call’s detail on China pricing and respiratory demand may drive the next move. 1–3 months: watch cash conversion, inventory, and restructuring charges versus realized savings. 6–18 months: China price changes could reset revenue economics structurally; growth outside China in Labs and Immunohematology offers some offset, but does not yet establish consolidated acceleration. Point-of-Care weakness may partly reverse with respiratory seasonality, so extrapolating this quarter’s decline is risky.

Contrarian point: the 3% constant-currency growth excluding named headwinds can look reassuring, but it removes several meaningful revenue pools; it is not a clean proxy for consolidated growth. Abbott, Roche, and Siemens Healthineers could benefit at the margin if customers redirect spending, but no evidence here establishes share gains. Thesis improves if cash generation turns sustainably positive and savings arrive without revenue erosion; it fails if China declines stabilize, POC rebounds, or restructuring delivers measurable margin and cash-flow gains.

Key Decisions for Investors

• Favor an underweight QDEL versus a diversified diagnostics peer basket over the next 1–3 months rather than an unconditional outright short; the setup is weaker guidance and cash conversion, but respiratory seasonality and low expectations may limit downside. Reassess after the conference-call outlook and next cash-flow disclosure.
• Treat the $80m savings target as an unverified catalyst, not earnings to capitalize today. Track restructuring charges against realized run-rate savings and customer/service indicators; downgrade the thesis if savings are delivered without weakening revenue or margins.
• Put QDEL liquidity on a watchlist: verify borrowing maturities, revolver availability, covenants, and whether inventory converts to cash. Escalate risk if operating cash flow remains negative or borrowing terms tighten; do not infer distress from current-debt classification alone.
• Avoid extrapolating Point-of-Care revenue weakness as structural until respiratory demand is clearer. A seasonal rebound alongside stabilization in China pricing would falsify the bearish relative-value view; persistent China declines and weak cash conversion would reinforce it.